Allogeneic hematopoietic stem cell transplantation (HSCT) has been performed mainly for young patients due to concern about the high incidence of treatmentrelated mortality (TRM). Recent advances to reduce TRM by using peripheral blood stem cells or nonmyeloablative conditioning regimens have increased the age limit for this procedure, and correctly identifying the indication for transplant is essential for older patients. In this study, we analyzed data from 398 patients aged 50 or over selected from 5147 patients, who received conventional allogeneic HSCT (c-HSCT). Patients aged 50 or older showed inferior outcomes for TRM and overall survival (OS). Mulitivariate analyses confirmed that an age of 50 or over was an independent risk factor for TRM (Po0.0001) and OS (Po0.0001). Among patients aged 50 or older, increasing age remained an adverse factor for OS (P ¼ 0.0213). Regimens including total-body irradiation (TBI) correlated with a higher risk of TRM and a lower OS for older patients (P ¼ 0.0095 and 0.0303, respectively). These findings indicate that allogeneic c-HSCT should be offered to patients over 50 years only if the increased risk of TRM is acceptable, and that a non-TBI regimen is preferable when the transplant is performed.
hematopoietic stem cell transplantation; total-body irradiation Allogeneic hematopoietic stem cell transplantation (HSCT) is now accepted as a curative therapy for patients with hematological malignancies and aplastic anemia. Despite its major potential as a cure, HSCT has been generally limited to younger patients due to concern about the high incidence of treatment-related mortality (TRM) for older patients. Recent advances have contributed to expanding its application. The use of peripheral blood (PB) cells instead of harvested bone marrow (BM) as a source of hematopoietic stem cells has been demonstrated to produce more rapid hematological recovery, [1] [2] [3] and has the advantage of a reduced risk of infectious complications during the early post transplant period. Moreover, development of nonmyeloablative transplantation (NST), a novel approach to reduce the intensity of conditioning regimens, has allowed older patients unsuitable for conventional HSCT (c-HSCT) to become transplant candidates. [4] [5] [6] These developments have made it necessary to decide on the appropriate option for older patients, especially those over 50 years, not only considering whether allogeneic HSCT should be performed, but also what type of transplant. The NST approach is now being investigated, but the effectiveness and safety of c-HSCT for such patients also needs evaluation. For this purpose, we analyzed data from 5147 patients who underwent allogeneic c-HSCT and whose transplants were reported to the Japan Society for Hematopoietic Cell Transplantation (JSHCT). A total of 398 patients over the age of 50 years were included in this study.
Patients and methods

Patients
The study population consisted of 5147 adult patients, 16 years of age or older, who were reported to the JSHCT as having undergone allogeneic c-HSCT for hematological disorders between January 1991 and December 2001. Patients who had received NST or cord blood transplantation were excluded, as were those who had undergone second or subsequent transplants. Information on surviving patients was updated annually. This study was approved by the Committee for Nationwide Survey Data Management of the JSHCT.
Statistical analysis
The primary end point of the analyses was to assess the influences of patient age on TRM and overall survival (OS). The secondary end point was to assess these effects on relapse, the development of grade II-IV acute graft-versushost disease (GVHD) and extensive chronic GVHD. Whole-population analyses compared patients aged 50 years or older to those younger than 50. The analyses of the subgroup including only patients aged over 50 were performed using age as a continuous variable. OS was defined as time from the day of transplant to death or last follow-up. Relapse was defined as hematological recurrence, and only those with malignant diseases were evaluated. Patients never achieving complete remission (CR) after transplant were considered to have had a recurrence on day 0. TRM was defined as death while in continuous CR. Acute and chronic GVHD were evaluated according to standard criteria. 7, 8 Those who died before engraftment were excluded from the analysis of acute GVHD, and those who died before day 100 were excluded from the analysis of chronic GVHD. The Cox proportional hazards regression model was used to evaluate the independent effect of age, sex, years of transplant, disease status, donor type, graft source, conditioning regimen and GVHD prophylaxis. Hazard ratio (HR) was calculated in conjunction with a 95% confidence interval (CI). For disease status, those with hematological malignancies in CR at the time of transplant, those in chronic phase of chronic myeloid leukemia (CML), those with refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) of myelodysplastic syndrome (MDS), and all those with nonmalignant diseases were defined as being at standard risk, while those in other situations were defined as being at advanced risk. All donors except for human leukocyte antigen (HLA)-identical siblings were classified as alternative donors. For assessment of the effect of graft source, patients receiving both BM and PB stem cells (2% of the entire population) were excluded. Patients receiving GVHD prophylaxis other than cyclosporine (CSP)-or tacrolimus (FK506)-based regimens (3% of the entire population) were excluded from assessment of the effects of GVHD prophylaxis. Distributions of variables between the two age groups were compared by using the w 2 test. Kaplan-Meier survival analyses were performed to estimate probability of OS, relapse and TRM. For relapse and TRM, each was used as a censored event for the other. Differences between groups were compared by means of the log-rank test. Stat View 5.0 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . The median age for the entire population was 34 years (range: . In all, 398 (8%) patients were 50 years of age or older (including 16 patients aged 60 years or older, and 77 patients aged 55-59 years), and 4749 (92%) patients were younger than 50 years. The two populations differed in the distributions of diagnosis, disease status, graft source, donor type and use of methotrexate (MTX). In the older group, the frequency of MDS and non-Hodgkin's lymphoma (NHL) was comparatively high, while that of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) was low. Older patients were more likely to be at advanced risk, to receive PB stem cells, to receive donations from HLA-identical siblings, and to receive no MTX. The distributions of sex, conditioning regimen (total-body irradiation [TBI] regimen vs non-TBI regimen) and GVHD prophylaxis (CSP-vs FK506-based regimen) were similar for the two groups. As shown in Figure 1 , the proportion of older patients undergoing allogeneic c-HSCT has increased over time.
Transplant outcome
The median follow-up period for surviving patients was 1208 days. TRM was significantly higher for the older group than for the younger group (log-rank, Po0.0001; Figure 2a ). The estimated probabilities were 16.5 vs 11.8% at 100 days, and 34.7 vs 22.7% at 1 year, respectively. The relapse rate was also higher for the older group than for the younger group, with respective probabilities of 36.4% and 29.7% at 4 years (log-rank, P ¼ 0.0042; Figure 2b ). Consequently, age at transplant strongly correlated with survival (log-rank, Po0.0001; Figure 2c ). The probability of OS at 4 years was 35.6% for patients 50 years or older, and 53.3% for those under 50 years.
Risk factor analysis
Nine pretransplant parameters were selected to be included for the subsequent multivariate analyses, ie, age group, sex, year of transplant, disease status, donor type, graft source, conditioning regimen and GVHD prophylaxis (CSP-vs FK506-based regimen and MTX vs no MTX). When the risk of GVHD was analyzed as times to events, patients aged 50 or older tended to be at greater risk of developing grade II-IV acute GVHD and extensive chronic GVHD (P ¼ 0.0886 and 0.0844, respectively). The results of multivariate analyses for outcome are shown in Table 2 . Although the age group had no effect on risk of relapse (P ¼ 0.3165), being 50 or older was associated with an increased risk of TRM (Po0.0001), and had a significantly negative impact on OS (Po0.0001). In addition to patient age, transplants performed in the early years, advanced risk disease, donation from alternative donors and omission of MTX were identified as adverse factors for both TRM and OS. Male sex and a CSP-based regimen also correlated with an increased risk of TRM. The risk of relapse was significantly higher among those with advanced risk disease and among those receiving transplants from HLA-identical siblings.
Analysis of the subgroup consisting of patients aged 50 or older
To identify the risk factors and their effect on transplant outcome in older patients, subgroup analyses were Figure 3 . TBI-containing regimens were associated with a higher probability of TRM without improvement of relapse rate, thus resulting in a significantly lower probability of OS (log-rank, P ¼ 0.0256 for TRM, P ¼ 0.6448 for relapse, and P ¼ 0.0255 for OS). The influence on TRM and OS was of statistical significance in multivariate analysis (P ¼ 0.0095 for TRM and P ¼ 0.0303 for OS).
Discussion
Allogeneic HSCT has been preferentially used for younger patients primarily due to concern about the high incidence of treatment-related morbidity and mortality. Generally, advanced age is considered to be a poor prognostic factor following HSCT. The major reasons for this are (1) underlying medical complications or organ dysfunction, (2) delay in drug metabolism potentiating the toxicity of conditioning regimens, and (3) a high incidence of GVHD as reported previously. [9] [10] [11] [12] Although the upper age limit for allogeneic HSCT has been set at around 50 years in many institutions, recent advances in HSCT have raised this limit. The use of PB instead of BM as a stem cell source has been demonstrated to reduce the duration of neutropenia, [1] [2] [3] which is especially beneficial for older patients exposed to a greater risk of life-threatening infection. Another major advance is the development of NST. The reduced toxicity of conditioning regimens has made it possible for this procedure to be used for older patients ineligible for c-HSCT. Published studies of NST have reported its use for patients in their 60s and even 70s. [4] [5] [6] Changes in recent years have expanded the range of treatment options, thus making assessment of c-HSCT for older patients an urgent necessity. In this study, we evaluated 398 older patients who underwent allogeneic c-HSCT and compared their outcomes with those for 4749 patients less than 50 years old. To our knowledge, this is the largest analytical study performed to date of allogeneic HSCT for patients aged 50 or older.
This study demonstrated that age 50 or more was strongly associated with a higher risk of TRM and inferior OS. Univariate analysis showed the effect of age on the incidence of relapse to be statistically significant, but multivariate analysis did not. This is attributable to the fact that advanced risk disease and transplantation from HLA-identical siblings, both of which were independent adverse factors for relapse, were more common among older patients. A study by the International Bone Marrow Transplant Registry (IBMTR) analyzed a total of 2180 leukemia patients, including 80 patients aged 50 or older, who had received allogeneic HSCT from HLA-identical siblings. 13 Patients were divided into four age groups and Figure 2 Treatment-related mortality, relapse and overall survival by age group. (a) The probability of treatment-related mortality was significantly higher for patients 50 years old or older (log-rank, Po0.0001). (b) Relapse rate was also higher for the older group (log-rank, P ¼ 0.0042), but the difference was not significant in multivariate analysis (P ¼ 0.3165). (c) Age at transplant was strongly associated with overall survival (log-rank, Po0.0001).
those with advanced leukemia and aged 45 or older showed a slightly higher risk of TRM, but no difference in leukemia-free survival was observed among age groups. Another study of a large series was that reported by the European Group for Bone Marrow Transplantation (EBMT), which compared 192 patients over 40 with 1119 younger patients.
14 Only those with AML and aged 45 or older were at higher risk of TRM but without any difference in terms of OS. These data as well as ours should be interpreted with caution because patients actually undergoing allogeneic HSCT are thought to be highly selected. However, in our study covering the largest number of patients to date, it should be emphasized that even highly selected patients showed poorer prognosis. It is in accordance with previously reported findings that the incidence of GVHD was higher in older patients, [9] [10] [11] [12] which almost reached statistical significance in our study. The higher incidence of GVHD has been proposed as one of the causes contributing to the higher risk of TRM.
Among patients aged over 50 years, increasing age remained an adverse factor for OS. As expected, advanced risk disease was associated with an inferior outcome in terms of relapse and OS. Notably, patients receiving a TBIcontaining regimen were at higher risk of TRM and demonstrated a lower probability of OS. Although radiation is effective as part of the conditioning regimen, no conclusion has been reached as to whether a TBI-containing regimen is superior or inferior to a non-TBI regimen. 15, 16 Two of five randomized controlled trials showed the superiority of TBI-regimens for survival. 17, 18 but no difference was observed in the other three trials. [19] [20] [21] It should be remembered that previous trials have not included older patients according to each eligibility criterion. In the study reported here, TBI-regimens were found to be more toxic and to worsen OS for patients over 50 years, while the detrimental effect of TBI was not demonstrated among younger patients. In summary, patient age at transplantation is a strong indicator for outcome after allogeneic c-HSCT. This treatment for patients aged 50 or older is associated with a higher risk of TRM and with a lower OS than for those under 50 years. Furthermore, conditioning regimens including TBI enhance negative effects. It is therefore suggested that allogeneic c-HSCT should be offered to patients 50 years of age or older only if the higher risk of TRM is acceptable. When the transplant is performed, a non-TBI regimen is preferable. Prospective comparative analyses of c-HSCT and NST are also needed for this population group. Figure 3 Treatment-related mortality, relapse and overall survival by conditioning regimen for patients aged 50 or older. TBI-containing regimens were associated with (a) higher incidence of TRM, (b) with no improvement of relapse rate (log-rank, P ¼ 0.0256 and 0.6448, respectively). (c) Patients aged 50 or older receiving a TBI-containing regimen showed poorer survival (log-rank, P ¼ 0.0255).
